Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- 5 Otsuka Execs Reel in 100 Million-Plus Pay in 2023: Securities Filing
April 1, 2024
- Chugai Workforce Down 200 in 2023 after Voluntary Buyout: Securities Report
April 1, 2024
- “Puberulic Acid” in Beni-Koji Supplements; Kobayashi Wants to Keep Healthcare Biz
April 1, 2024
- Uber Eats Launches Delivery Service for Prescription Drugs in Japan
March 29, 2024
- Taiho Bags Label Update for Lonsurf Combo Use with Bevacizumab
March 29, 2024
- BIKEN Files Nasal Flu Vaccine in Japan
March 29, 2024
- Padcev/Keytruda Accepted for Chinese Review for 1st Line Bladder Cancer Use
March 29, 2024
- Sumitomo-Sponsored Trial for Parkinson’s Cell Therapy to Commence in US
March 29, 2024
- Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
March 29, 2024
- Fuso Says Toray Jacked Up Damage Claim in Remitch Patent Suit
March 28, 2024
- Sosei Group to Be Renamed “Nxera Pharma” from April
March 28, 2024
- Abilify Maintena Gets EU Nod as 1st 2-Month Injectable for Schizophrenia
March 28, 2024
- AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
- Incyte Appoints Eiji Ueda as Japan Chief
March 27, 2024
- SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
- One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
- Kobayashi’s Beni Koji Health Damage Reports Trigger Knock-On Recalls
March 27, 2024
- CureApp Files Alcoholism Therapy App in Japan
March 26, 2024
- Eisai Settles Lenvima Patent Suit with Sun Pharma
March 26, 2024
- EMA Panel Gives Go-Ahead for Xtandi Use in Earlier Setting: Astellas
March 26, 2024
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…